#USA #New York #Class Action #Securities Fraud #Immutep Limited

Class Action Lawsuit for Immutep Limited Investors

Investors in Immutep Limited, a biopharmaceutical company, have recently been alerted to a class action lawsuit following significant stock losses resulting from the collapse of the TACTI-004 clinical trial. On March 13, 2026, shares plummeted from $2.76 to $0.48, marking an astounding 83% decline in a single day, which translates to a financial loss of $2.28 per share. This drastic drop has raised serious concerns among shareholders, prompting the lawsuit spearheaded by the legal team at SueWallSt.

The Allegations

The lawsuit names three high-ranking executives from Immutep as individual defendants: Marc Voigt, the company’s CEO; Frédéric Triebel, the Chief Scientific Officer; and Stephan Winckels, the Chief Medical Officer. All are accused of exercising control over the company’s public communications and SEC filings throughout the specified class period, which spans from March 24, 2025 to March 12, 2026.

The premise of the complaint is based on Section 20(a) of the Securities Exchange Act, which holds individuals liable who control actions that lead to misleading statements affecting investors. The lawsuit claims that these executives had access to critical internal data regarding the TACTI-004 trial's progress and deliberately withheld adverse information from the investing public, essentially masking the study’s potential failure.

The Control and Misconduct

Each defendant is alleged to have:

• - Had the authority to influence the contents of the SEC reports and press releases.
• - Been privy to material non-public information related to the clinical trial.
• - Failed to correct misleading statements made to investors despite the knowledge of risk concerning the trial's efficacy.

The complaint further accuses them of breaching their certification obligations under the Sarbanes-Oxley Act, which enforces accuracy in financial reporting. It argues that the executives knowingly certified misleading filings at the expense of shareholder interest.

Investors' Rights and Next Steps

The class action lawsuit aims to return investor losses by asserting that these top executives acted with scienter, which means they had actual knowledge or were grossly negligent regarding the misleading nature of their public disclosures.

Investors interested in joining the class action have a deadline to apply for lead plaintiff status by July 6, 2026. Even if shares have been sold, investors may still participate if lost during the class period.

If you are an affected investor, it is advised to gather relevant brokerage documents—such as purchase dates and quantities—before contacting SueWallSt for a free evaluation. The legal process does not require plaintiffs to appear in court and operates on a no win, no fee basis, eliminating the risk of upfront costs.

SueWallSt has built a reputation over the past seven years as a leading firm in shareholder rights litigation, recovering substantial sums for investors across various cases. They encourage affected Immutep shareholders to take action promptly to protect their rights and seek recourse for the apparent corporate misconduct.

For more information, please reach out to Joseph E. Levi at [email protected] or call (888) SueWallSt.